|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,421,762
Summary
U.S. Patent 4,421,762, issued on December 20, 1983, to Johnson & Johnson, covers a pharmaceutical composition and method involving a specific type of topical steroid. This patent primarily pertains to the formulation of a corticosteroid-based topical preparation for dermatological use, emphasizing a particular combination and method of application. Its scope primarily encompasses novel compositions with claimed improvements over existing formulations, notably in enhanced efficacy and reduced side effects.
The patent claims are substantial, defining a broad yet precise scope around the composition and associated methods of use. This analysis maps the claims to the broader patent landscape by examining similar patents, prior art, and subsequent filings, highlighting potential patent thickets, freedom-to-operate considerations, and avenues for innovation or potential challenges.
1. Introduction to Patent 4,421,762
Patent details:
- Title: Topical corticosteroid compositions
- Assignee: Johnson & Johnson
- Filing date: September 12, 1980
- Issue date: December 20, 1983
- Patent number: 4,421,762
The patent claims a specific topical corticosteroid formulation characterized by a combination of active compounds, a particular carrier, and a method of administration aimed at treating dermatologic conditions such as dermatitis.
2. Scope of the Patent: Key Elements and Coverage
2.1 Composition Claims
| Claim Number |
Content Summary |
Key Components |
Scope Focus |
| Claim 1 |
A topical corticosteroid composition |
A corticosteroid (e.g., betamethasone dipropionate) + a carrier |
Broad coverage of corticosteroid formulations with specified carriers |
| Claim 2 |
The composition of Claim 1 with an additional specific excipient |
Emphasis on carriers compatible with corticosteroids |
Focused on formulations with specific excipients |
| Claim 3-5 |
Methods of applying the composition to treat skin conditions |
Application methods |
Method claims protecting use |
2.2 Core Claims Breakdown
- Active Ingredient: Primarily corticosteroids such as betamethasone dipropionate, designed to provide anti-inflammatory effects.
- Formulation Type: Emulsions, creams, or ointments with specific carriers enhancing absorption or stability.
- Method of Use: Topical application for dermatological conditions, such as eczema or psoriasis.
2.3 Claim Scope Analysis
- Breadth: Includes composition and method claims relating to specific corticosteroid concentrates with defined carriers.
- Limitations: Focused on topical applications with particular carriers like petroleum jelly or alcohol-based solutions.
- Implications: Offers broad coverage for formulations containing the specified corticosteroids, potentially overlapping with later corticosteroid patents.
3. Patent Landscape Context
3.1 Prior Art and Foundation
- Pre-1983 corticosteroid formulations included various topical steroids, with previous patents detailing active compounds, carriers, or application methods.
- Key prior art references:
- U.S. Patent 4,091,228 (1978): Betamethasone formulations
- U.S. Patent 3,950,454 (1976): Topical corticosteroid carriers
3.2 Subsequent Related Patents
| Patent Number |
Filing Date |
Assignee |
Focus |
Relevance to 4,421,762 |
| U.S. Patent 4,592,834 |
August 1984 |
Schering |
Corticosteroid formulations with enhanced skin penetration |
Building on similar carrier technology |
| U.S. Patent 5,240,776 |
September 1991 |
Johnson & Johnson |
Novel corticosteroid delivery systems |
Further innovation within similar scope |
Observation: The patent landscape includes multiple corticosteroid formulations, with Johnson & Johnson maintaining a strong portfolio of related patents, indicating a strategic position around specific compounds and carriers.
3.3 Patent Term and Expiry
- The patent, filed in 1980 and issued in 1983, generally expired in 2000, opening the market for generic formulations.
- Overlap with later patents could impact market entry or product development during the patent’s lifespan.
4. Claim Typology and Patent Strategies
4.1 Composition Claims Focus
- Broad claims cover various corticosteroid-carrier combinations.
- Narrower claims specify particular corticosteroid derivatives.
- Strategy: Protect a range of formulations within a defined therapeutic class.
4.2 Method Claims
- Cover methods of applying the formulations, emphasizing treatment protocols.
- Strategy: Extend patent coverage to beyond composition, including method of use.
4.3 Regulatory and Commercial Implications
- The patent’s claims can influence stability, bioavailability, and efficacy data requirements.
- Generic challengers must navigate patent claims via design-around strategies or challenge the validity.
5. Comparative Analysis with Similar Patents
| Aspect |
U.S. Patent 4,421,762 |
Competing Patents |
Notable Differences |
| Active Ingredient |
Betamethasone dipropionate |
Clobetasol propionate, Fluocinonide |
Different corticosteroids with varying potency |
| Carrier Focus |
Specific carriers enhancing absorption |
Liposomes, nanoparticle carriers |
Broader or alternative delivery systems |
| Application Scope |
Topical dermatological uses |
Invasive or systemic applications |
Focused on dermatology |
6. Legal and Commercial Significance
- The patent solidified Johnson & Johnson's position in corticosteroid topical therapies during the 1980s.
- It provided patent protection during critical market expansion phases, reducing competition.
- Its expiration facilitated the entry of generics, impacting market share and pricing.
7. Future Patent Landscape Trends
| Trend |
Implication |
Example |
| Next-generation transdermal systems |
Focus on nanotechnology or microneedles |
Pioneering sustained-release corticosteroid patches |
| Novel carriers |
Use of lipid-based nanocarriers |
Enhancing skin penetration, reducing dosage |
| Combination therapies |
Corticosteroids + immunomodulators |
Expanding therapeutic scope |
8. Conclusions
U.S. Patent 4,421,762 has historically played a significant role in laying the foundation for topical corticosteroid formulations. Its broad claims on specific compositions and methods of application defined the market landscape during its enforceability period. The patent’s landscape reveals a strategic positioning that shaped subsequent innovation and competition. While the original patent has expired, its legacy persists in the continued development of advanced dermatological drug delivery systems.
Key Takeaways
- The patent's broad composition and method claims provided comprehensive coverage for corticosteroid topical formulations.
- Overlapping patents and prior art necessitate careful freedom-to-operate analyses for new entrants.
- Post-expiry, the landscape opened for generics, but innovation continues in the realm of delivery mechanisms and combination therapies.
- Innovation strategies should focus on alternative carriers, formulations, and combination treatments to navigate around existing patents.
- Continuous monitoring of patent filings by major players like Johnson & Johnson remains critical for intellectual property management.
FAQs
Q1: What are the primary corticosteroids covered under U.S. Patent 4,421,762?
A1: The patent primarily covers corticosteroids such as betamethasone dipropionate, used for topical anti-inflammatory treatments.
Q2: How does this patent influence current dermatological drug formulations?
A2: While expired, it historically shaped formulation strategies, influencing subsequent patents focused on delivery systems and combination therapies.
Q3: Are there similar patents covering other corticosteroid delivery systems?
A3: Yes, subsequent patents, such as U.S. Patent 4,592,834, cover advanced delivery mechanisms like enhanced skin penetration methods.
Q4: What challenges might generic manufacturers face based on this patent?
A4: They need to ensure formulations do not infringe on the composition or method claims, or demonstrate patent invalidity if applicable.
Q5: What are the emerging areas of innovation inspired by patents like 4,421,762?
A5: Innovations include nanoparticle carriers, transdermal patches, and combination treatments that build on the foundational principles established by this patent.
References
[1] U.S. Patent 4,421,762, "Topical corticosteroid compositions," Johnson & Johnson, issued December 20, 1983.
[2] Prior art references and subsequent patents cited in the patent file.[1]
[3] Industry analysis reports on topical corticosteroid formulations, 1980–2020.
More… ↓
⤷ Start Trial
|
